ストックスクリーナーアプリを入手
0.1705
8.82%
-0.0165
アフターアワーズ：
.18
0.0095
+5.57%
前日終値:
$0.187
開ける：
$0.187
24時間の取引高:
1.43M
Relative Volume:
2.63
時価総額：
$7.82M
収益：
$300.00K
当期純損益:
$-21.46M
株価収益率:
-0.0673
EPS:
-2.5324
ネットキャッシュフロー:
$-14.40M
1週間 パフォーマンス:
-13.01%
1か月 パフォーマンス:
-24.22%
6か月 パフォーマンス:
-52.45%
1年 パフォーマンス:
-47.38%
1日の値動き範囲:
$0.1668
$0.1876
1週間の範囲:
$0.1668
$0.1956
52週間の値動き範囲:
$0.1628
$0.492
Theriva Biologics Inc Stock (TOVX) Company Profile
名前
Theriva Biologics Inc
セクター
電話
301 417 4364
住所
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.1705 | 7.82M | 300.00K | -21.46M | -14.40M | -2.5324 |
VRTX
Vertex Pharmaceuticals Inc
|
558.88 | 141.65B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
927.89 | 95.53B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
221.72 | 88.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
892.87 | 56.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.33 | 41.89B | 5.76B | 514.49M | 1.10B | 4.4813 |
Theriva Biologics Inc (TOVX) 最新ニュース
Theriva Biologics, Inc. Estimates – AMEX:TOVX - TradingView
Theriva Biologics Proposes 500 Million Share Increase and Warrant Ratification for November 18 Meeting - Kalkine Media
Stockholders face another vote on $0.54 warrants at Theriva Biologics (TOVX). - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Price & News - Syfe
Form PRE 14A Theriva Biologics Inc For: 9 October By Investing.com - Investing.com Nigeria
Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.
Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada
Theriva™ Biologics Announces Publication of the Results - GlobeNewswire
Theriva Biologics Inc. (TOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Theriva Biologics Inc. (TOVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theriva Biologics Inc. (TOVX) Peer Comparison – Compare with Others - Value Research
Theriva Biologics Inc. (TOVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DaySaaS Earnings Trends - careplusvn.com
Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportPCR Divergence - dars.gov.et
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportVolatility Skew - careplusvn.com
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportStock News - dars.gov.et
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportFactor Crowding - dars.gov.et
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneUp Down Volume - https://www.siam.in/
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportBuy Signal Reports - https://www.dars.gov.et/
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Canada
Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative
Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView
Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan
Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com
Theriva Biologics: Q2 Earnings Snapshot - AOL.com
Theriva Biologics: Q2 Earnings Snapshot - KTVB
Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo
BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics: Q2 Earnings Snapshot - finance.yahoo.com
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics Doses First Patients in VIRAGE2 Phase 2a Trial of Repeated VCN-01 Dosing in Metastatic Pancreatic Cancer - Quiver Quantitative
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Yahoo Finance
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com South Africa
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan
Theriva Biologics Inc (TOVX) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):